We are excited to announce that OncoRNA has been selected as a direct partner in the Med4Cure EU program. This prestigious selection allows us to access up to €30.42M in non-dilutive funding.Our mission of OncoRNA is to manufacture and commercialize Personalized RNA Cancer Immuno-Therapy (PRCIT) potentially a fast, high-performant, and cost-effective personalized immunotherapies for cancer patients. We have developed a novel approach to personalised oncology vaccines. Our unique technology offers significant advantages over existing methods, including the ability to encode over 100 individualized neoantigens simultaneously in a single tube. This eliminates the need for a narrow selection of antigens and allows for a three-week turnaround time from tumor biopsy to personalized vaccine. Additionally, our process is cost-effective and well-suited for automation.We have demonstrated the production process, shown antigen expression in mice, and are moving toward IND. We have also secured the necessary agreements and partnerships for clinical production and trials.